Key result
Cardiac Parvovirus B19 prevalence showed no difference between myocarditis or dilated cardiomyopathy patients and healthy control hearts, leaving its independent pathogenetic importance unclear.
Why the study?
Does the presence of cardiac parvovirus B19 (B19V) have pathogenetic and prognostic relevance in myocarditis and dilated cardiomyopathy?
Does the presence of cardiac parvovirus B19 (B19V) have pathogenetic and prognostic relevance in myocarditis and dilated cardiomyopathy?
The presence of cardiac parvovirus B19 alone does not differ between myocarditis/DCM patients and healthy controls, suggesting that viral load, replicative status, and co-infections are key to its pathogenetic relevance.
No takes yet. Share an insight, caveat, or question.
B19V detection alone should not guide MC/DCM management; leaves open the role of viral load, replication, and co-infections.
Verdonschot et al. (2016) conducted a review in Myocarditis and Dilated Cardiomyopathy. Cardiac Parvovirus B19 (B19V) vs. Healthy control hearts was evaluated on Prevalence of B19V. Cardiac Parvovirus B19 prevalence showed no difference between myocarditis or dilated cardiomyopathy patients and healthy control hearts, leaving its independent pathogenetic importance unclear.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: